StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $1.18M, down 95.9% from the year before. The highest annual figure on record is $28.94M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.18M-95.9%
FY2024Dec 31, 2024$28.94M+502.9%
FY2023Dec 31, 2023$4.80M–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$294.00K–
Q2 FY2025Jun 30, 2025$304.00K–
Q2 FY2024Jun 30, 2024$5.39M–
Q2 FY2023Jun 30, 2023$0–

More BioLineRx figures

See a number that looks wrong?